Page 19 - hypertension_newsletter

REFLECTIONS
Hypertension
Hypertension Global Newsletter #10 2026

TREATMENT AND BIOMARKERS Hypertension

4. Aldosterone synthase inhibitors for resistant or uncontrolled hypertension: A network meta-analysis of randomized
clinical trials. Elbahloul MA, et al. J Hypertens. 2026 Apr 1;44(4):542-552.

5. High blood pressure in childhood and premature cardiovascular disease mortality. Freedman AA, et al. JAMA. 2025
Nov 4;334(17):1555-1557.
6. Medication adherence in hypertension: A cluster randomized clinical trial. Blecker S, et al. JAMA Cardiol. 2025 Sep
1;10(9):914-921.

7. Integrative proteomic profiling of blood pressure and hypertension. Aggarwal M, et al. Hypertension. 2026
Jun;83(6):e26407.

BLOOD PRESSURE MANAGEMENT

8. Impact of intensive versus standard blood pressure control on cardiovascular events in hypertensive patients: A
meta-analysis of randomized controlled trials. Prizão VM, et al. J Hypertens. 2026 Jan 1;44(1):49-55.

9. Frailty index offers greater discrimination than age for optimal blood pressure targets: A pooled analysis of two
randomized trials. Lyu Y, et al. Hypertension. 2026 Jun;83(6):e26397.
10. Uncontrolled hypertension in young adults: A real-world analysis of 89,130 adults in the United States. Islam S, et
al. Hypertension. 2026 Mar;83(3):e26081.

11. Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on
cardiovascular and renal outcomes: An individual participant data analysis of randomised controlled trials. Guo X,
et al. Lancet. 2025 Sep 6;406(10507):1009-1019.

TABLE OF CONTENTS